While elevated m6A levels are generally considered oncogenic, the m6A eraser FTO has emerged as a promising therapeutic target in certain AML subtypes and, notably, in acquired TKI resistance in both AML and CML [44]. The gene discussed is FTO; the disease is acute myeloid leukemia.